Table 1.
Published KETO and MDZ data sets
| Sources | Dose (mg) | Sample size per subject (time frame) | Size (M/F) | Meal |
|---|---|---|---|---|
| KETO | ||||
| [24] | 200 capsule | 5 (1–24 h) | 3 (N/A) | Fasting |
| 200 solution | 5 (1–24 h) | 3 (N/A) | Fasting | |
| 100,200,400 tablet | 8 (0.5–48 h) | 12 (N/A) | Meal | |
| 200 solution | 8 (0.5–48 h) | 12 (N/A) | Meal | |
| [25] | 200, 400 tablet | 14 (0.5–48 h) | 28–44 6(6/0) | Meal |
| [26] | 200 tablet, 7(0–24 h) | 10 (0.5–8 h) | 8 (8/0) | Fasting |
| [27] | 200, 400, 600 800, tablet | 13 (0.5, 32 h) | 8 (3/5) (20–31) | Meal |
| [28] | 200 solution suspension, tablet | 12 (0.5–48 h) | 24 (24/0) | Fasting |
| 200, 400, 800 solution | 12 (0.5–48 h) | 12 (24/0) | Fasting | |
| Novopharm Ltd | 200 tablet | 17 (1/4–24 h) | 39 (39/0) | Fasting |
| (FDA, 1999) | 200 tablet | 17 (1/4–24) | 23 (24/0) | Meal |
| TEVA Pharm. | 200 tablet | 15 (1/3–48) | 24 (24/0) | Fasting |
| (FDA, 1999) | 200 tablet | 15 (1/3–48) | 17 (17/0) | Meal |
| MDZ | ||||
| [29] | 2 IV fusion | 27 (1/2–6 h) | 12 (6/6) | Fasting |
| [10] | 2 IV | 12 (1/4–8 h) | 9 (6/3) | Fasting |